Pfizer Inc. said Thursday it spent $177 million in 2010 on payments to doctors and other health care professionals for a mix of research, speeches, and other services. The report is part of a movement by drug developers to disclose payments they make to physicians after years of scrutiny that the practice wasn’t transparent. Pharmaceutical companies often pay physicians a fee to “educate” their …

Pharmaceutical company spent $177 million in 2010 on payments to doctors and other health care professionals for a mix of research, speeches, and other services.

Pfizer Inc. said Thursday it spent $177 million in 2010 on payments to doctors and other health care professionals for a mix of research, speeches, and other services.

NORTH MYRTLE BEACH - During the North Myrtle Beach Public Safety Department’s March 26 community medicine drop-off day, 45,147 dosage units of medicine were collected. 

The Genetics Policy Institute (GPI) and Future Medicine have announced that its 2011/12 World Stem Cell Report will be published as a special supplement to the award- winning, peer-reviewed journal Regenerative Medicine. It was also announced that Regenerative Medicine becomes the platinum media sponsor of the GPI’s 2011 World Stem Cell Summit that will take place in Pasadena, California …

Mind over matter

Headache Remedy: To fix its recurring Tyenol problems, Johnson & Johnson is revamping its McNeil Consumer Healthcare unit, which sells the pain medication, the WSJ reports. The reorganization will make McNeil a stand-alone unit and is the latest effort by the New Brunswick, N.J., health-care-products company to fix quality problems that have prompted recalls, damaged […]

Giving girls with Turner syndrome low doses of estrogen, as well as growth hormone, years before the onset of puberty, increases their height and offers a wealth of other benefits, say a team of researchers led by Thomas Jefferson University.

Glaxo and Valeant have received marketing authorization for their epilepsy drug, Trobalt.

Data from a recent report from BioTrends Research Group suggest that U.S. fibromyalgia patients who are currently taking one of the three agents approved for the treatment of fibromyalgia – Eli Lilly’s Cymbalta, Pfizer’s Lyrica, and Forest Laboratories/Cypress Biosciences’ Savella – may have higher expectations for their treatment than patients taking off-label therapies.